Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer

This study was designed to assess the safety and efficacy of capecitabine and mitomycin C (MMC) in previously untreated patients with advanced colorectal cancer (CRC). Patients received capecitabine 2500 mg m(2) day 1, orally divided in two doses of 1250 mg m(−2) in the morning and evening for 14 da...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Rao, S, Cunningham, D, Price, T, Hill, M E, Ross, P J, Tebbutt, N, Norman, A R, Oates, J, Shellito, P
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2004
Soggetti:
Clinical
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2409883/
https://ncbi.nlm.nih.gov/pubmed/15266319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602039
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi